Media Releases and Opportunities
» Go to news mainMedia opportunity: Researchers discover drug used in treatment of Alzheimer's effectively reduces damage caused by traumatic brain injury without harmful side‑effects
Researchers have for decades studied ways to reduce the effects of trauma on the nervous system, but medical therapies that alleviate the short- and long-term consequences of traumatic brain injury have yet to be approved.
One of the effects of these injuries is cortical spreading depolarization (CSD), a process that alters the electrical signals and blood flow of the brain. In can occur in the "healthy" brain without severe harm, as with migraine auras. However, it can be harmful for patients with traumatic brain injuries, leading to worse clinical outcomes for many who experience this phenomenon.
In a new animal study, researchers at Dalhousie University examined the effect of both moderate and mild repetitive concussive head impacts on CSD. They monitored the brain’s electrical activity and blood flow response during microsurgery. They also tested therapies to inhibit CSD, hoping to find one that would not cause unwanted side-effects linked to other previously studied drugs used to treat CSD, like ketamine.
They found that memantine, a N-methyl-D-aspartate-receptor antagonist used in the treatment of Alzheimer's, inhibited CSD as effectively as ketamine, with no observable side-effects. It also improved the brain's electrical activity and blood flow response following traumatic brain injury.
Memantine prevented neurological decline following repetitive concussive brain impacts, according to the study published in the journal Science Advances.
Dr. Mark MacLean, a neurosurgery resident at Dalhousie, led the study and is available to discuss how this research demonstrates that memantine effectively reduces the harms of CSD, does not cause side-effects and sets the stage for future clinical trials in humans with acquired brain injuries.
-30-
Media contact:
Alison Auld
Senior Research Reporter
Communications, Marketing and Creative Services
Dalhousie University
Cell: 1-902-220-0491
Email: alison.auld@dal.ca
Recent News
- Media opportunity: Being involved in extracurricular activities really does matter when it comes to 'mattering': Dalhousie University research
- Media opportunity: Podcast by Dalhousie researcher and Halifax photographer looks at barriers to Nova Scotia's coastline, decreasing access to waterfronts and problems with litter, marine debris in public coastal areas
- Media opportunity: Dalhousie University researcher pioneers new cancer treatment ‑‑ cutting‑edge CAR‑T cell therapy
- Media opportunity: Research sheds light on the difficulty temporary foreign workers can face in securing permanent residency in P.E.I.
- Media opportunity: World's largest stores of unfrozen freshwater projected to warm and affect cold‑water habitats, geothermal energy resources and drinking water quality : Dalhousie University research
- Media release: Dalhousie University research reveals conservation benefits are doubled for reef sharks and rays in fully protected marine areas that also have strong fisheries management
- Media release: New program partners Dalhousie researcher and IWK Health to tackle violence against women
- Media opportunity: Dalhousie University researchers and an international team identify new strain of mpox virus in Africa that can spread through heterosexual sex and community contact
Comments
comments powered by Disqus